Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.31B |
$17.19
+1.12%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$1.29B |
$21.65
-0.23%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.28B |
$17.44
-0.06%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.27B |
$27.35
-1.23%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$1.25B |
$65.79
+9.01%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$1.24B |
$17.39
+0.75%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.23B |
$5.49
+3.98%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$1.22B |
$7.69
+3.50%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.21B |
$83.74
+1.28%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.20B |
$17.46
+2.36%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$1.20B |
$10.76
+1.80%
|
|
KOD
Kodiak Sciences Inc.
Kodiak is developing ophthalmic drugs (intravitreal biologics) for retinal diseases, making Ophthalmic Drugs a core product category.
|
$1.19B |
$22.44
-2.39%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.18B |
$42.15
+1.57%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.17B |
$22.01
+0.50%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.16B |
$7.18
+1.20%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$1.16B |
$39.98
+0.13%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.15B |
$11.82
+1.72%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.14B |
$12.91
+8.03%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.14B |
$33.86
+7.15%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.13B |
$6.95
+3.89%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.11B |
$3.75
+2.18%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.11B |
$99.68
+5.07%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.09B |
$10.59
-3.46%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.09B |
$3.63
+0.41%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$1.08B |
$15.18
+1.67%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.07B |
$29.41
+2.90%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$1.07B |
$23.82
+2.78%
|
|
OPK
OPKO Health, Inc.
OPK-88006 is a dual GLP-1/glucagon peptide therapeutic (peptide therapeutics).
|
$1.06B |
$1.35
|
Showing page 8 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
